View source for GLP-1 weight loss injections

{{Short description|GLP-1 agonists for weight loss, diabetes, sleep apnea, and W8MD medical weight loss programs}}
{{Infobox drug
| drug_name              = GLP-1 agonists
| image                  = [[File:Before-and-after-weight-loss.jpeg |250px]]
| caption                = Before and after weight loss pictures
| tradename              = [[Wegovy]], [[Ozempic]], [[Rybelsus]], [[Zepbound]], [[Mounjaro]], [[Saxenda]], [[Victoza]], [[Trulicity]]
| generic_name           = [[Semaglutide]], [[tirzepatide]], [[liraglutide]], [[dulaglutide]], [[exenatide]], [[lixisenatide]]
| drug_class             = [[GLP-1 receptor agonist]], [[incretin mimetic]], [[anti-obesity medication]], [[diabetes medication]]
| routes_of_administration = Subcutaneous injection; oral formulation available for selected [[semaglutide]] products
| uses                   = [[Weight loss]], [[obesity]], [[type 2 diabetes]], [[cardiovascular risk]] reduction in selected patients, [[obstructive sleep apnea]] in selected adults with obesity using [[Zepbound]]
| mechanism              = Appetite reduction, delayed gastric emptying, increased glucose-dependent insulin secretion, reduced glucagon secretion, improved satiety
| related                = [[GLP-1]], [[GIP]], [[glucagon]], [[semaglutide]], [[tirzepatide]], [[liraglutide]], [[retatrutide]]
}}
[[File:Weight-loss-150.png|thumb|right|300px|[[GLP-1 weight loss injections]] may help selected patients reduce appetite, improve satiety, lose weight, and improve obesity-related health conditions.]]
[[File:W8MD-Team.jpg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] can evaluate patients for [[GLP-1 weight loss]] medications when medically appropriate.]]
[[File:Woman-losing-weight.jpeg|thumb|right|350px|GLP-1 medications work best when combined with nutrition, protein planning, physical activity, sleep optimization, and long-term maintenance.]]

'''GLP-1 agonists''', also called '''GLP-1 receptor agonists''' or '''incretin-based medications''', are a class of medications that mimic or activate the effects of [[glucagon-like peptide-1]] or related gut hormones involved in appetite, blood sugar regulation, insulin secretion, gastric emptying, and satiety. They are used in the treatment of [[type 2 diabetes]], [[obesity]], [[overweight]] with weight-related medical problems, and selected cardiometabolic conditions.

Important GLP-1 and related medications include [[semaglutide]], [[liraglutide]], [[tirzepatide]], [[dulaglutide]], [[exenatide]], and [[lixisenatide]]. Common brand names include [[Wegovy]], [[Ozempic]], [[Rybelsus]], [[Saxenda]], [[Victoza]], [[Zepbound]], [[Mounjaro]], and [[Trulicity]]. Newer investigational agents include [[retatrutide]], a triple-receptor agonist targeting [[GIP]], [[GLP-1]], and [[glucagon]] receptors.

'''[[W8MD Weight Loss, Sleep and MedSpa]] Centers''' can help eligible patients access physician-supervised [[GLP-1 weight loss injections]] such as [[Wegovy]], [[Ozempic]], [[Zepbound]], [[Mounjaro]], [[semaglutide]], and [[tirzepatide]] when medically appropriate. W8MD also helps patients combine these medications with [[medical weight loss]], [[nutrition]], [[meal replacements]], [[low-carbohydrate diet]] planning, [[sleep apnea]] evaluation, and long-term [[weight loss maintenance]].

==Overview==
GLP-1 agonists are not simply “diet shots.” They are medical treatments that affect appetite, satiety, glucose regulation, digestion, and body weight. They should be used under medical supervision, especially in patients with diabetes, high blood pressure, kidney disease, gastrointestinal disorders, gallbladder disease, pancreatitis history, pregnancy considerations, or other medical problems.

GLP-1 medications may help with:

{{div col|colwidth=18em}}
* [[Weight loss]]
* Reduced appetite
* Improved satiety
* Lower [[hemoglobin A1c]]
* Improved [[insulin resistance]]
* Reduced food cravings in some patients
* Improved [[cardiometabolic risk]]
* Reduced [[triglycerides]] in some patients
* Improved [[fatty liver disease]] risk factors in some patients
* Reduced [[sleep apnea]] severity in selected patients with obesity
* Long-term [[weight maintenance]] when continued and monitored
{{div col end}}

==What is GLP-1?==
[[GLP-1]], or [[glucagon-like peptide-1]], is a hormone released from the gut after eating. It helps regulate appetite and blood sugar.

GLP-1 actions include:

{{div col|colwidth=18em}}
* Increasing glucose-dependent insulin secretion
* Reducing glucagon secretion when glucose is high
* Slowing gastric emptying
* Increasing fullness
* Reducing appetite
* Supporting post-meal blood sugar control
{{div col end}}

==How GLP-1 agonists work==
GLP-1 agonists bind to GLP-1 receptors and extend the effects of natural GLP-1. Because natural GLP-1 is broken down quickly, medication versions are modified to last longer.

They may promote weight loss through:

{{div col|colwidth=20em}}
* Reduced appetite
* Increased satiety
* Smaller meal size
* Reduced snacking
* Delayed gastric emptying
* Improved blood sugar control
* Reduced food reward in some patients
* Improved insulin sensitivity indirectly through weight loss
{{div col end}}

==GLP-1 agonists and weight loss==
GLP-1 medications are widely used in [[medical weight loss]] because they address appetite biology, not just willpower. Many patients with [[obesity]], [[insulin resistance]], [[prediabetes]], [[PCOS]], [[metabolic syndrome]], [[fatty liver disease]], and [[sleep apnea]] struggle with hunger, cravings, and weight regain. GLP-1-based therapy can help selected patients reduce calorie intake and improve adherence to a structured plan.

A successful GLP-1 weight-loss program should include:

{{div col|colwidth=20em}}
* Medical evaluation
* BMI and weight-history review
* Medication review
* Nutrition planning
* Protein intake support
* Hydration
* Physical activity
* Resistance training
* Monitoring for side effects
* Sleep apnea screening when appropriate
* Long-term maintenance planning
{{div col end}}

==FDA-approved GLP-1 and related medications==
===Semaglutide===
[[Semaglutide]] is a GLP-1 receptor agonist used in several products.

Common semaglutide brands include:

{{div col|colwidth=18em}}
* [[Wegovy]] - used for chronic weight management and selected cardiovascular risk reduction indications
* [[Ozempic]] - used for [[type 2 diabetes]]
* [[Rybelsus]] - oral semaglutide used for [[type 2 diabetes]]
{{div col end}}

The FDA approved Wegovy for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and in 2024 approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 27, 2026}} DailyMed describes Wegovy as semaglutide injection, a human GLP-1 receptor agonist or GLP-1 analog.{{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564|title=WEGOVY - semaglutide injection, solution|publisher=DailyMed, National Library of Medicine|accessdate=June 27, 2026}}

===Tirzepatide===
[[Tirzepatide]] is a dual [[GIP]] and [[GLP-1]] receptor agonist. It activates both glucose-dependent insulinotropic polypeptide receptors and GLP-1 receptors.

Common tirzepatide brands include:

{{div col|colwidth=18em}}
* [[Zepbound]] - used for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity
* [[Mounjaro]] - used for [[type 2 diabetes]]
{{div col end}}

DailyMed describes Zepbound as tirzepatide injection containing tirzepatide, a GIP receptor and GLP-1 receptor agonist.{{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b|title=ZEPBOUND - tirzepatide injection, solution|publisher=DailyMed, National Library of Medicine|accessdate=June 27, 2026}}

===Liraglutide===
[[Liraglutide]] is an older GLP-1 receptor agonist.

Common liraglutide brands include:

{{div col|colwidth=18em}}
* [[Saxenda]] - used for chronic weight management
* [[Victoza]] - used for [[type 2 diabetes]]
{{div col end}}

Liraglutide is typically administered once daily, unlike many newer GLP-1-based medications that are administered once weekly.

===Dulaglutide===
[[Dulaglutide]], sold as [[Trulicity]], is a once-weekly GLP-1 receptor agonist used for [[type 2 diabetes]]. It is not primarily a weight-loss medication, but weight changes may occur in some patients.

===Exenatide===
[[Exenatide]] is an earlier GLP-1 receptor agonist used for [[type 2 diabetes]]. It has been marketed as [[Byetta]] and [[Bydureon]].

===Lixisenatide===
[[Lixisenatide]] is a GLP-1 receptor agonist used for [[type 2 diabetes]] and has been marketed as [[Adlyxin]].

==Emerging GLP-1 and related medications==
===Retatrutide===
[[Retatrutide]] is an investigational triple-hormone-receptor agonist that targets [[GIP]], [[GLP-1]], and [[glucagon]] receptors. It is sometimes misspelled as “ritatrutide.” Retatrutide is not yet an FDA-approved medication for weight loss, but it has shown promising results in clinical trials.

A phase 2 trial published in the ''New England Journal of Medicine'' reported that once-weekly retatrutide produced substantial weight reduction at 24 and 48 weeks, with dose-dependent efficacy, and the authors concluded that the findings supported further phase 3 investigation.{{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|doi=10.1056/NEJMoa2301972|pmid=37366315}}

Because retatrutide remains investigational, patients should not purchase research peptides, online “retatrutide,” or unapproved products marketed for human use. Such products may be unsafe, unregulated, counterfeit, contaminated, or incorrectly dosed.

===Orforglipron===
[[Orforglipron]] is an investigational oral non-peptide GLP-1 receptor agonist being studied for obesity and type 2 diabetes. If approved in the future, oral GLP-1 options may expand treatment choices for patients who prefer tablets over injections.

===CagriSema===
[[CagriSema]] is an investigational combination of [[cagrilintide]] and [[semaglutide]] being studied for obesity. Cagrilintide is an amylin analog, while semaglutide is a GLP-1 receptor agonist.

===Other pipeline agents===
Other investigational agents may target multiple hormonal pathways, including GLP-1, GIP, glucagon, amylin, and other appetite and metabolic signaling systems.

==Comparison of selected GLP-1 and related medications==
{| class="wikitable"
! Medication
! Brand names
! Main receptor action
! Common use
! Status
|-
| [[Semaglutide]]
| [[Wegovy]], [[Ozempic]], [[Rybelsus]]
| [[GLP-1 receptor agonist]]
| Weight management, type 2 diabetes, selected cardiovascular risk reduction
| FDA-approved for selected uses
|-
| [[Tirzepatide]]
| [[Zepbound]], [[Mounjaro]]
| [[GIP]] and [[GLP-1 receptor agonist]]
| Weight management, type 2 diabetes, moderate-to-severe OSA in adults with obesity using Zepbound
| FDA-approved for selected uses
|-
| [[Liraglutide]]
| [[Saxenda]], [[Victoza]]
| [[GLP-1 receptor agonist]]
| Weight management, type 2 diabetes
| FDA-approved for selected uses
|-
| [[Dulaglutide]]
| [[Trulicity]]
| [[GLP-1 receptor agonist]]
| Type 2 diabetes
| FDA-approved
|-
| [[Exenatide]]
| [[Byetta]], [[Bydureon]]
| [[GLP-1 receptor agonist]]
| Type 2 diabetes
| FDA-approved
|-
| [[Lixisenatide]]
| [[Adlyxin]]
| [[GLP-1 receptor agonist]]
| Type 2 diabetes
| FDA-approved
|-
| [[Retatrutide]]
| Investigational
| [[GIP]], [[GLP-1]], and [[glucagon]] receptor agonist
| Obesity research
| Investigational, not FDA-approved
|}

==Brand names and common confusion==
Patients often confuse brand names and generic names.

{| class="wikitable"
! Generic name
! Weight-loss brand
! Diabetes brand
! Notes
|-
| [[Semaglutide]]
| [[Wegovy]]
| [[Ozempic]], [[Rybelsus]]
| Wegovy is used for weight management; Ozempic and Rybelsus are diabetes brands
|-
| [[Tirzepatide]]
| [[Zepbound]]
| [[Mounjaro]]
| Zepbound is used for weight management and moderate-to-severe OSA in adults with obesity; Mounjaro is a diabetes brand
|-
| [[Liraglutide]]
| [[Saxenda]]
| [[Victoza]]
| Saxenda is a daily injection for weight management
|}

==Zepbound and obstructive sleep apnea==
[[Zepbound]] is important for W8MD because it can connect [[medical weight loss]] and [[sleep medicine]]. In December 2024, the FDA approved Zepbound as the first medication for moderate-to-severe [[obstructive sleep apnea]] in adults with obesity.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 27, 2026}}

The FDA stated that Zepbound’s approval was based on two randomized, double-blind, placebo-controlled studies in adults with moderate-to-severe OSA and obesity, including one study in patients using positive airway pressure and one in patients unable or unwilling to use it.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 27, 2026}}

==Who may qualify for GLP-1 weight loss medications?==
Eligibility depends on medical history, BMI, insurance requirements, medication availability, contraindications, and clinician judgment. Many weight-loss medication guidelines use criteria such as:

{{div col|colwidth=18em}}
* [[BMI]] of 30 or higher
* BMI of 27 or higher with weight-related medical conditions
* [[Hypertension]]
* [[Prediabetes]]
* [[Type 2 diabetes]]
* [[Dyslipidemia]]
* [[Sleep apnea]]
* [[Fatty liver disease]]
* [[PCOS]]
* [[Metabolic syndrome]]
{{div col end}}

Final eligibility should be determined by a qualified healthcare provider.

==Common side effects==
Common GLP-1 and related medication side effects may include:

{{div col|colwidth=18em}}
* Nausea
* Vomiting
* Diarrhea
* Constipation
* Abdominal discomfort
* Heartburn
* Reduced appetite
* Bloating
* Injection-site reactions
* Fatigue in some patients
{{div col end}}

Side effects often occur during dose escalation and may improve with slower eating, smaller portions, lower-fat meals, hydration, and medical dose adjustment.

==Important warnings and precautions==
GLP-1 and related medications are not appropriate for everyone. DailyMed labeling for Wegovy includes a boxed warning about thyroid C-cell tumors observed in rodents and states that it is unknown whether semaglutide causes medullary thyroid carcinoma in humans.{{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564|title=WEGOVY - semaglutide injection, solution|publisher=DailyMed, National Library of Medicine|accessdate=June 27, 2026}}

Patients should discuss risks with a healthcare provider, especially if they have:

{{div col|colwidth=20em}}
* Personal or family history of medullary thyroid carcinoma
* Multiple endocrine neoplasia syndrome type 2
* Pancreatitis history
* Gallbladder disease
* Severe gastrointestinal disease
* Kidney disease
* Pregnancy or plans for pregnancy
* Breastfeeding
* Eating disorder history
* Use of insulin or sulfonylureas
* Dehydration risk
{{div col end}}

==Nutrition while using GLP-1 medications==
GLP-1 medications reduce appetite, but nutrition quality remains essential. Patients may eat less, so every meal should count.

W8MD may advise patients to focus on:

{{div col|colwidth=18em}}
* Protein-first meals
* Smaller portions
* Hydration
* Fiber as tolerated
* Non-starchy vegetables
* Avoiding greasy meals if nausea occurs
* Avoiding sugary drinks
* Avoiding overeating despite fullness
* Resistance training
* Electrolytes when appropriate
* Long-term maintenance planning
{{div col end}}

==Muscle preservation==
Weight loss can include both fat loss and lean mass loss. GLP-1 patients should protect muscle through:

{{div col|colwidth=18em}}
* Adequate protein
* Strength training
* Resistance exercises
* Hydration
* Sleep quality
* Avoiding excessive calorie restriction
* Medical monitoring
{{div col end}}

==W8MD affordable GLP-1 weight loss options==
'''[[W8MD Weight Loss, Sleep and MedSpa]] Centers''' offer physician-supervised GLP-1 weight-loss care for eligible patients in [[New York City]], [[Brooklyn]], [[New Jersey]], [[Philadelphia]], and the [[Greater Philadelphia]] area.

W8MD may help eligible patients with:

{{div col|colwidth=20em}}
* [[GLP-1 weight loss injections]]
* [[Wegovy]]
* [[Ozempic]]
* [[Zepbound]]
* [[Mounjaro]]
* [[Semaglutide]]
* [[Tirzepatide]]
* [[Liraglutide]]
* [[Saxenda]]
* Traditional [[diet pills]]
* [[Meal replacements]]
* [[Low-carbohydrate diet]]
* [[Ketogenic diet]]
* [[Sleep apnea]] evaluation
* Long-term [[weight loss maintenance]]
{{div col end}}

==Limited-time W8MD GLP-1 special==
<div style="border:2px solid #f2c94c;background:#fff8df;padding:14px;margin:12px 0;border-radius:10px;">
'''Affordable GLP-1 weight loss shots - limited time special'''

W8MD offers [[GLP-1 weight loss injections]] such as [[Wegovy]], [[Ozempic]], [[Zepbound]], [[Mounjaro]], [[semaglutide]], and [[tirzepatide]] when medically appropriate.

* '''Affordable GLP-1 options starting at $29.99/week and up''' with insurance for visits for eligible patients.
* '''Most insurances accepted''' for qualifying medical visits.
* '''Self-pay GLP-1 injection options starting from $59.99/week and up''' when available and medically appropriate.
* Pricing, insurance coverage, medication access, and eligibility vary by patient, location, medication, pharmacy availability, and medical evaluation.
</div>

==How W8MD can help==
W8MD can help patients determine whether GLP-1-based treatment is appropriate and safe.

W8MD may provide:

{{div col|colwidth=20em}}
* Physician-supervised [[medical weight loss]]
* GLP-1 medication evaluation
* Review of medical history and contraindications
* Insurance visit support
* Prior authorization support when available
* Self-pay options when available
* Nutrition planning
* [[Meal replacements]]
* Protein planning
* Side-effect management
* Weight-loss plateau support
* [[Sleep apnea]] screening
* [[Home sleep test]] when appropriate
* [[Zepbound]] evaluation for adults with obesity and moderate-to-severe OSA when appropriate
* Long-term [[weight maintenance]]
{{div col end}}

==GLP-1 medications and sleep medicine==
Many patients with obesity also have undiagnosed [[obstructive sleep apnea]], which can worsen fatigue, cravings, blood pressure, insulin resistance, and difficulty losing weight. W8MD’s combined focus on medical weight loss and sleep medicine allows patients to address both conditions.

Sleep symptoms to discuss include:

{{div col|colwidth=18em}}
* Snoring
* Daytime sleepiness
* Morning headaches
* Waking up choking or gasping
* Witnessed pauses in breathing
* Fatigue despite sleep
* High blood pressure
* Weight gain or difficulty losing weight
{{div col end}}

==Why medical supervision matters==
GLP-1 medications should be used with medical supervision because dosing, side effects, medication interactions, and eligibility vary by patient. Unsupervised online products may be unsafe.

Medical supervision helps with:

{{div col|colwidth=18em}}
* Correct medication selection
* Dose escalation
* Side-effect management
* Monitoring hydration and nutrition
* Preventing excessive muscle loss
* Avoiding unsafe drug combinations
* Adjusting diabetes medications
* Monitoring blood pressure
* Long-term maintenance
{{div col end}}

==Avoid unapproved GLP-1 products==
Patients should avoid buying unapproved online “research” peptides, counterfeit semaglutide, counterfeit tirzepatide, or investigational products such as retatrutide sold for human use outside legitimate clinical trials. Such products may be unsafe, mislabeled, contaminated, or illegally marketed.

==GLP-1 treatment and long-term maintenance==
GLP-1 medications work best as part of a long-term plan. Stopping medication without a maintenance strategy may lead to weight regain in many patients.

Maintenance strategies include:

{{div col|colwidth=18em}}
* Continued medical follow-up
* Protein-first eating
* Strength training
* Sleep apnea treatment
* Meal planning
* Weight monitoring
* Relapse prevention
* Medication continuation when appropriate
* Transition planning if medication is stopped
{{div col end}}

==Frequently asked questions==
===Are GLP-1 medications the same as diet pills?===
No. GLP-1 medications are hormone-based injectable or oral medications that affect appetite, satiety, and glucose regulation. Traditional diet pills such as [[phentermine]] work differently.

===Is semaglutide the same as Wegovy?===
[[Semaglutide]] is the generic active ingredient. [[Wegovy]] is the brand used for weight management. [[Ozempic]] and [[Rybelsus]] are semaglutide brands used for type 2 diabetes.

===Is tirzepatide the same as Zepbound?===
[[Tirzepatide]] is the generic active ingredient. [[Zepbound]] is the brand used for weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. [[Mounjaro]] is the diabetes brand.

===Is retatrutide available now?===
[[Retatrutide]] is investigational and not FDA-approved. It should not be purchased online or used outside legitimate clinical trials.

===Can W8MD help with GLP-1 shots?===
Yes. W8MD can evaluate patients for GLP-1 weight-loss injections when medically appropriate, help with nutrition, provide sleep apnea screening, and support long-term maintenance.

===Does W8MD accept insurance?===
W8MD accepts most insurances for qualifying medical visits. Affordable GLP-1 options may start at $29.99/week and up with insurance for visits for eligible patients.

===What if I do not have insurance?===
Self-pay GLP-1 injection options may start from $59.99/week and up when available and medically appropriate. Pricing and eligibility vary.

===Can Zepbound help sleep apnea?===
Yes. [[Zepbound]] is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Patients may still need CPAP, APAP, BiPAP, sleep testing, lifestyle treatment, or other care depending on medical evaluation.

==When to call a doctor==
Seek medical advice before starting GLP-1 therapy if you have:

{{div col|colwidth=18em}}
* Type 1 diabetes
* Type 2 diabetes using insulin or sulfonylureas
* Kidney disease
* Pancreatitis history
* Gallbladder disease
* Severe gastrointestinal disease
* Pregnancy or breastfeeding
* Eating disorder history
* Medullary thyroid cancer history
* Multiple endocrine neoplasia type 2
* Severe nausea, vomiting, dehydration, or abdominal pain
{{div col end}}

==Conclusion==
GLP-1 agonists and related incretin-based medications have changed the treatment of obesity, type 2 diabetes, cardiometabolic risk, and selected sleep apnea care. Medications such as [[semaglutide]], [[tirzepatide]], and [[liraglutide]] can help selected patients lose weight when combined with medical supervision, healthy nutrition, protein planning, physical activity, sleep optimization, and long-term maintenance. Emerging agents such as [[retatrutide]] may expand future options but remain investigational until approved. [[W8MD Weight Loss, Sleep and MedSpa]] can help eligible patients access affordable GLP-1 weight-loss care, evaluate medication options, screen for sleep apnea, and build a sustainable plan for long-term health.

==See also==
{{div col|colwidth=18em}}
* [[GLP-1]]
* [[GLP-1 receptor agonist]]
* [[GLP-1 weight loss]]
* [[Weight loss injections]]
* [[Medical weight loss]]
* [[Semaglutide]]
* [[Wegovy]]
* [[Ozempic]]
* [[Rybelsus]]
* [[Tirzepatide]]
* [[Zepbound]]
* [[Mounjaro]]
* [[Liraglutide]]
* [[Saxenda]]
* [[Victoza]]
* [[Retatrutide]]
* [[Orforglipron]]
* [[CagriSema]]
* [[Obesity]]
* [[Overweight]]
* [[Insulin resistance]]
* [[Prediabetes]]
* [[Type 2 diabetes]]
* [[Metabolic syndrome]]
* [[Sleep apnea]]
* [[Obstructive sleep apnea]]
* [[W8MD Weight Loss, Sleep and MedSpa]]
{{div col end}}

==Relevant WikiMD links==
* [https://wikimd.org/wiki/Semaglutide Semaglutide]
* [https://wikimd.org/wiki/Tirzepatide Tirzepatide]
* [https://wikimd.org/wiki/Wegovy Wegovy]
* [https://wikimd.org/wiki/Ozempic Ozempic]
* [https://wikimd.org/wiki/Zepbound Zepbound]
* [https://wikimd.org/wiki/Mounjaro Mounjaro]
* [https://wikimd.org/wiki/Liraglutide Liraglutide]
* [https://wikimd.org/wiki/Saxenda Saxenda]
* [https://wikimd.org/wiki/Victoza Victoza]
* [https://wikimd.org/wiki/Retatrutide Retatrutide]
* [https://wikimd.org/wiki/GLP-1 GLP-1]
* [https://wikimd.org/wiki/GLP-1_receptor_agonist GLP-1 receptor agonist]
* [https://wikimd.org/wiki/Weight_loss Weight loss]
* [https://wikimd.org/wiki/Medical_weight_loss Medical weight loss]
* [https://wikimd.org/wiki/Obesity Obesity]
* [https://wikimd.org/wiki/Sleep_apnea Sleep apnea]

==Further reading==
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 27, 2026}}
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 27, 2026}}
* {{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564|title=WEGOVY - semaglutide injection, solution|publisher=DailyMed, National Library of Medicine|accessdate=June 27, 2026}}
* {{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b|title=ZEPBOUND - tirzepatide injection, solution|publisher=DailyMed, National Library of Medicine|accessdate=June 27, 2026}}
* {{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|doi=10.1056/NEJMoa2301972|pmid=37366315}}

==External links==
* [https://nycmedicalweightloss.com NYC medical weight loss]
* [https://w8md.org Philadelphia medical weight loss]
* [https://wikimd.org/wiki/Semaglutide Semaglutide on WikiMD]
* [https://wikimd.org/wiki/Tirzepatide Tirzepatide on WikiMD]
{{GLP-1}}
{{DEFAULTSORT:GLP-1 Agonists}}
[[Category:GLP-1]]
[[Category:GLP-1 receptor agonists]]
[[Category:GLP-1 weight loss]]
[[Category:Weight loss injections]]
[[Category:Medical weight loss]]
[[Category:Anti-obesity medication]]
[[Category:Obesity]]
[[Category:Semaglutide]]
[[Category:Tirzepatide]]
[[Category:Liraglutide]]
[[Category:Retatrutide]]
[[Category:Wegovy]]
[[Category:Ozempic]]
[[Category:Zepbound]]
[[Category:Mounjaro]]
[[Category:Saxenda]]
[[Category:Type 2 diabetes]]
[[Category:Insulin resistance]]
[[Category:Metabolic syndrome]]
[[Category:Sleep apnea]]
[[Category:W8MD]]